CIC and Babraham Bioscience Technologies are among the co-founders of Start Codon, a life sciences accelerator set to invest in up to 50 seed-stage startups over the next five years.

Based at DCU Invent, Deciphex has gained investors including Inova and GI Partners as it looks to refine its offering for the toxicologic and gastrointestinal segments of pathology.

Applied Morphomics has formally spun out of University of Michigan to deliver a medical analytics service powered by morphological scans of patients.

Building on Chiba and Hokkaido university research, Think-Lands is aiming to commercialise microneedles manufactured with its optical vortex production system.

Building on KU Leuven and Amsterdam UMC research, Cytura hopes to find small molecule candidates that combat the issue of genomic variability in cancer.

The gene therapy developer's latest round featured a $75m investment from Novartis and was closed as it withdrew its IPO application.

Talaris, previously known as Regenerex and based on research at University of Louisville, will use the funding to advance its cell therapy into later-stage clinical development.

Gilead Sciences, Boehringer Ingelheim and Takeda all recorded exits as immunotherapy developer Hookipa went public, floating at the bottom of its range.

Celgene and Pfizer returned for small molecule drug developer Arrakis Therapeutics' latest round, which included GV and Wuxi AppTec Fund.

Osage University has returned for a $75m series B round raised by Arrakis Therapeutics, which has licensed technology from University of Pennsylvania.